Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: dutasteride, abiraterone | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 1 stopped | 0.60 |
| literature PubMed | 1 Parkinson's papers of 352 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10211
Sealed predictions
- SRD5A1 in dopamine neurons, braak+0.55 (p 0.125) → -0.06 (p 0.873)receipt 10218
Swarm cases
receipt 10218: SRD5A1 in dopamine neurons, braak
- power
- full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.567, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.351, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.34, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SRD5A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts